Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/kalbe-farma-tbk-pt">Kalbe Farma</a> is the largest publicly-listed pharmaceutical company in Indonesia and Southeast Asia, with a diversified business model spanning four key divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution &amp; Logistics.</li>
  <li>The company is well-positioned to capitalize on the favorable long-term tailwinds of the Indonesian healthcare industry, which is the largest in ASEAN and projected to continue its strong growth trajectory, driven by a large population, a rising middle class, and the national health insurance scheme (JKN/BPJS).</li>
  <li>Despite recent margin pressures from a shifting product mix and currency fluctuations, the stock appears attractively valued, trading at a significant discount to its historical mean. A rebound in revenue, coupled with stable raw material prices and a resilient core profit outlook, presents a compelling investment case.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Kalbe Farma is the largest publicly-listed pharmaceutical company in Indonesia and Southeast Asia, with a diversified business model spanning four key divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution &amp; Logistics.
  The company is well-positioned to capitalize on the favorable long-term tailwinds of the Indonesian healthcare industry, which is the largest in ASEAN and projected to continue its strong growth trajectory, driven by a large population, a rising middle class, and the national health insurance scheme (JKN/BPJS).
  Despite recent margin pressures from a shifting product mix and currency fluctuations, the stock appears attractively valued, trading at a significant discount to its historical mean. A rebound in revenue, coupled with stable raw material prices and a resilient core profit outlook, presents a compelling investment case.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Indonesia

PT Kalbe Farma Tbk produces and develops pharmaceutical products for human and animal healthcare.  Through its subsidiaries, the Company also operates in the pharmaceutical, health food, and packaging industries.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kalbe Farma (KLBF IJ)

Primer: Kalbe Farma (KLBF IJ) - Dec 2025

Kalbe Farma is the largest publicly-listed pharmaceutical company in Indonesia and Southeast Asia, with a diversified business model spanning...

αSK

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)